文献速递血栓与止血

2-O,3-O去硫酸肝素减轻小鼠化疗和放疗诱导的血小板减少症

2-O, 3-O desulfated heparin mitigates murine chemotherapy- and radiation-induced thrombocytopenia.
PubMed 文献 · Blood Adv · 2018-01-01

研究探讨2-O,3-O去硫酸肝素(ODSH)中和血小板因子4(PF4)对巨核细胞生成抑制作用的能力。体外实验显示ODSH使PF4处理的巨核细胞集落恢复至17.4%(P<.01);小鼠化疗和放疗诱导血小板减少症模型中,损伤后24小时开始给ODSH,治疗组血小板计数最低值为9%±5%而对照组为4%±4%,治疗组生存率73%而对照组36%。作者认为ODSH可能成为化疗和放疗诱导血小板减少症的重要临床相关治疗。

要点

  • ODSH使PF4处理的巨核细胞培养中巨核细胞集落恢复至17.4%(P<.01)。
  • 小鼠模型中损伤后24小时开始ODSH,治疗组血小板最低值9%±5% vs 对照组4%±4%。
  • 治疗组生存率73% vs 对照组36%。

核心结论

  • ODSH通过中和髓内负旁分泌PF4减轻小鼠化疗和放疗诱导的血小板减少症。
  • ODSH已在人类临床试验中作为化疗辅助用药,可能成为化疗和放疗诱导血小板减少症的重要临床相关治疗。

研究设计与样本

  • 体外巨核细胞集落分析和液体培养实验,使用PF4处理的Cxcl4-/-小鼠及人CD34+来源的巨核细胞培养。
  • 小鼠化疗诱导血小板减少症和放疗诱导血小板减少症模型,损伤后24小时开始给ODSH,观察造血恢复。

主要发现

  • ODSH使PF4处理的Cxcl4-/-小鼠和人CD34+来源巨核细胞培养中巨核细胞集落恢复至17.4%(P<.01,与PF4相比)。
  • 小鼠化疗和放疗诱导血小板减少症模型中,ODSH治疗组血小板计数最低值为9%±5%而对照组为4%±4%。
  • 治疗组生存率73%而对照组36%,治疗动物生存显著改善。
  • 免疫组化分析显示ODSH能降低髓内游离PF4浓度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Thrombocytopenia is a significant complication of chemotherapy and radiation therapy. Platelet factor 4 (PF4; CXCL4) is a negative paracrine of megakaryopoiesis. We have shown that PF4 levels are inversely related to steady-state platelet counts, and to the duration and severity of chemotherapy- and radiation-induced thrombocytopenia (CIT and RIT, respectively). Murine studies suggest that blocking the effect of PF4 improves megakaryopoiesis, raising nadir platelet counts and shortening the time to platelet count recovery. We examined the ability of 2-O, 3-O desulfated heparin (ODSH), a heparin variant with little anticoagulant effects, to neutralize PF4's effects on megakaryopoiesis. Using megakaryocyte colony assays and liquid cultures, we show that ODSH restored megakaryocyte proliferation in PF4-treated Cxcl4-/- murine and human CD34+-derived megakaryocyte cultures (17.4% megakaryocyte colonies, P < .01 compared with PF4). In murine CIT and RIT models, ODSH, started 24 hours after injury, was examined for the effect on hematopoietic recovery demonstrating higher platelet count nadirs (9% ± 5% treated vs 4% ± 4% control) and significantly improved survival in treated animals (73% treated vs 36% control survival). Treatment with ODSH was able to reduce intramedullary free PF4 concentrations by immunohistochemical analysis. In summary, ODSH mitigated CIT and RIT in mice by neutralizing the intramedullary negative paracrine PF4. ODSH, already in clinical trials in humans as an adjuvant to chemotherapy, may be an important, clinically relevant therapeutic for CIT and RIT.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Tkaczynski E, Arulselvan A, Tkaczynski J, et al. 2-O, 3-O desulfated heparin mitigates murine chemotherapy- and radiation-induced thrombocytopenia. Blood Adv. 2018. PMID: 29599195. doi:10.1182/bloodadvances.2017013672

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。